Lataa...
Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone: Cohort Study of FDA and Sponsor Communication, 2011-2017
This cohort study of FDA- and drug sponsor–written communications evaluates the communication of nonefficacy benefits of new drugs approved on the basis of noninferiority trials alone.
Tallennettuna:
| Julkaisussa: | JAMA Intern Med |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Medical Association
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6503639/ https://ncbi.nlm.nih.gov/pubmed/30830158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2018.7040 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|